In this review, therefore, we focus on the TGF-β signaling pathway and selective intervention strategies as a background to discuss problems related to pharmacological inhibitors for TGF-β family members used in preclinical and clinical cancer studies. The gene discussed is TGFB1; the disease is cancer.